Muvalaplin, an Oral Small-Molecule Inhibitor of Lipoprotein(a) Formation
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial
JAMA 2023 Aug 28;[EPub Ahead of Print], SJ Nicholls, SE Nissen, C Fleming, S Urva, J Suico, PH Berg, H Linnebjerg, G Ruotolo, PK Turner, LF MichaelFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.